Buy This Undervalued Biotech Now

Capstone is currently trading at a third its value.
Author:
Publish date:

Updated from 12:16 p.m. EST

With the merger between

Pfizer

(PFE) - Get Report

and

Wyeth

(WYE)

, the attempted takeover of

Genentech

(DNA)

by Roche, rumors of a potential buyout of

Acorda Therapeutics

(ACOR) - Get Report

by

Biogen Idec

(BIIB) - Get Report

, and the overall positive action in

Amgen

(AMGN),

Celgene

(CELG) - Get Report

,

Genzyme

(GENZ)

and

Gilead

(GILD) - Get Report

recently, many analysts and investors believe that 2009 will be a positive year for the biotech industry as a whole.

Important events in the biotech space include

Dendreon's

(DNDN)

binary data announcement on its key drug Provenge in early April and Genentech's update on various uses for Avastin late April.

Taking a step back from the more commonly covered biotech names, let's look at

Capstone Therapeutics

(CAPS)

, formally called Orthologic, ticker symbol OLGC.

How would you like to buy a $1.14 stock for less than 40 cents?

To read more,

visit Stockpickr.com

.

Stockpickr is a wholly owned subsidiary of TheStreet.com.